Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
MLYS Mineralys Therapeutics
15.650+0.800+5.39%
Close
03/30 16:00 ET
15.6500.0000.00%
Post Mkt Price 03/30 16:01 ET
High
15.790
Open
14.760
Turnover
1.61M
Low
14.392
Pre Close
14.850
Volume
104.90K
Post
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Stocks That Hit 52-Week Lows On Tuesday
 On Tuesday, 74 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows: First Majestic Silver (NYSE:AG) was the biggest company in terms of market cap to set a new 5
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 7.7%
Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Rating) shares traded down 7.7% during mid-day trading on Tuesday . The company traded as low as $13.71 and last traded at $13.71. 56,476 shares changed
Dermatology Drug Developer Azitra Upsizes Proposed IPO to $20M
Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) Quiet Period Set To End on March 22nd
Mineralys Therapeutics' (NASDAQ:MLYS – Get Rating) quiet period is set to expire on Wednesday, March 22nd. Mineralys Therapeutics had issued 12,000,000 shares in its public offering on February 10th.
Mineralys Therapeutics (NASDAQ:MLYS) Hits New 12-Month Low on Analyst Downgrade
Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Rating) reached a new 52-week low on Friday after Credit Suisse Group lowered their price target on the stock from $40.00 to $38.00. Credit Suisse Group
Credit Suisse Adjusts Mineralys Therapeutics' Price Target to $38 From $40, Keeps Outperform Rating
10:35 AM EDT, 03/16/2023 (MT Newswires) -- Mineralys Therapeutics (MLYS) has an average rating of buy and price targets ranging from $27 to $45, according to analysts polled by Capital IQ. Price: 16.6
Sector Update: Health Care Stocks Mixed Premarket Thursday
09:17 AM EDT, 03/16/2023 (MT Newswires) -- Health care stocks were mixed premarket Thursday. The Health Care Select Sector SPDR Fund (XLV) was declining 0.3% and the iShares Biotechnology ETF (IBB) wa
Where Mineralys Therapeutics Stands With Analysts
Analysts have provided the following ratings for Mineralys Therapeutics (NASDAQ:MLYS) within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings33000Last 30D010001
Mineralys Therapeutics Price Target Cut to $38.00/Share From $40.00 by Credit Suisse
Mineralys Therapeutics Is Maintained at Outperform by Credit Suisse
Mineralys Therapeutics Is Maintained at Outperform by Credit Suisse
